AC
BMY icon

Armistice Capital’s Bristol-Myers Squibb BMY Stock Holding History

Armistice Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Sell
205,024
-167,442
-45% -$9.76M 0.22% 81
2025
Q4 		$20.1M Sell
372,466
-277,267
-43% -$13.3M 0.24% 71
2025
Q3 		$29.3M Buy
+649,733
New +$30.3M 0.43% 34
2024
Q3 		– Sell
-490,868
Closed -$20.4M – 265
2024
Q2 		$20.4M Buy
+490,868
New +$22M 0.26% 66
2023
Q4 		– Sell
-529,613
Closed -$30.7M – 311
2023
Q3 		$30.7M Buy
529,613
+129,613
+32% +$7.94M 0.47% 42
2023
Q2 		$25.6M Buy
+400,000
New +$26.8M 0.37% 53
2022
Q4 		– Sell
-600,000
Closed -$42.7M – 202
2022
Q3 		$42.7M Sell
600,000
-556,000
-48% -$40.3M 0.74% 36
2022
Q2 		$89K Sell
1,156,000
-240,000
-17% -$18.3M 1.55% 12
2022
Q1 		$102M Sell
1,396,000
-928,000
-40% -$62.3M 1.97% 9
2021
Q4 		$145M Sell
2,324,000
-32,000
-1% -$1.88M 2.37% 4
2021
Q3 		$139M Buy
2,356,000
+678,000
+40% +$44.7M 2.36% 4
2021
Q2 		$112M Buy
1,678,000
+178,000
+12% +$11.6M 2.01% 6
2021
Q1 		$94.7M Buy
1,500,000
+464,000
+45% +$28.9M 2.17% 4
2020
Q4 		$64.3M Buy
1,036,000
+36,000
+4% +$2.21M 2.19% 7
2020
Q3 		$60.3M Hold
1,000,000
– – 2.19% 8
2020
Q2 		$58.8M Buy
1,000,000
+352,000
+54% +$21.1M 2.58% 5
2020
Q1 		$36.1M Buy
648,000
+148,000
+30% +$9.05M 2.23% 12
2019
Q4 		$32.1M Buy
+500,000
New +$28.6M 1.85% 13

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's BMY Position: Q1 2026 in Review

Armistice Capital reduced its Bristol-Myers Squibb (BMY) stake by 45% in Q1 2026, selling an estimated $9.76M and leaving 205,024 shares worth $12.4M. The position accounts for 0.22% of the portfolio, ranked #81.

Armistice Capital first reported a position in BMY in Q4 2019 and has held it in 18 quarters since. The position peaked at $145M in Q4 2021. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Armistice Capital held 205,024 shares of Bristol-Myers Squibb worth $12.4M as of Q1 2026.
  • Armistice Capital sold 167,442 Bristol-Myers Squibb shares in Q1 2026, an estimated $9.76M.
  • Bristol-Myers Squibb made up 0.22% of Armistice Capital's portfolio in Q1 2026, its #81 holding.
  • Armistice Capital first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 18 quarters since.
  • Armistice Capital's Bristol-Myers Squibb position peaked at $145M in Q4 2021.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.